To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Tasquinimod inhibits pros… - University of Gothenburg, Sweden Till startsida
Sitemap
To content Read more about how we use cookies on gu.se

Tasquinimod inhibits prostate cancer growth in bone through alterations in the bone microenvironment.

Journal article
Authors Lisa U. Magnusson
Malin Hagberg Thulin
Pascale Plas
Anders Olsson
Jan-Erik Damber
Karin Welén
Published in The Prostate
Volume 76
Issue 4
Pages 383–393
ISSN 1097-0045
Publication year 2016
Published at Institute of Clinical Sciences, Department of Urology
Pages 383–393
Language en
Links dx.doi.org/10.1002/pros.23133
Subject categories Urology and Nephrology

Abstract

Tasquinimod (ABR-215050) is an orally active quinoline-3-carboxamide analog that inhibits occurrence of experimental metastasis and delays disease progression of castration resistant prostate cancer in humans. Its mechanism of action is not fully elucidated, but previous studies show immunomodulatory and anti-angiogenic effects. The aim of the present study was to investigate the tumor inhibiting effect of tasquinimod in bone of castrated mice as well as to elucidate its working mechanism related to bone microenvironment.

Page Manager: Webmaster|Last update: 9/11/2012
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?